Objectives: Localized cutaneous leishmaniasis and its evolving forms diffuse cutaneous leishmaniasis, mucosal leishmaniasis and cutaneous leishmaniasis recidivans, together with the visceral leishmaniasis sequelae post-kala azar dermal leishmaniasis account for about one million dermal leishmaniases cases per year worldwide. Although not lethal, the dermal leishmaniases cause chronic and disfiguring skin lesions, which are an important cause of morbidity and stigma. Microscopy remains the reference test for diagnosis of dermal leishmaniasis; however, it has low and variable sensitivity and requires well trained personnel. The technical complexity and cost of the more sensitive molecular techniques (e.g. PCR) limits their application in routine diagnosis in endemic areas. Point-of-care (POC) tests for early diagnosis are much needed in order to benefit both patients and communities, by reducing the risk of both sequelae and Leishmania transmission. To this end we developed a Target Product Profile (TPP) for a POC test for dermal leishmaniases.
Introduction
The leishmaniases are a group of infections caused by parasites of the genus Leishmania, which are transmitted through the bite of female phlebotomine sand flies, through either a zoonotic or anthroponotic cycle (WHO Expert Committee on the Control of the Leishmaniases and World Health Organization, 2010) . Most dermal leishmaniasis cases are localized cutaneous leishmaniasis (CL) but other more aggressive forms include, diffuse cutaneous leishmaniasis (DCL), mucosal leishmaniasis (ML) and cutaneous leishmaniasis recidivans (CLR), which in total account for an estimated 0.7-1.2 million cases/year worldwide (Alvar et al., 2012) . Another form of dermal leishmaniasis is post-kala azar dermal leishmaniasis (PKDL), a complication of visceral leishmaniasis (VL) caused by Leishmania donovani that affects up to 5% of VL cases in the Indian subcontinent and up to 50% in eastern Africa. PKDL patients may also play an important role in transmission of L. donovani (World Health Organization, 2013; Zijlstra et al., 2017) . Although not lethal, dermal leishmaniases cause chronic and disfiguring skin lesions, which are an important cause of morbidity and social stigma (Toledo Jr et al., 2013; Kassi et al., 2008; Nilforoushzadeh et al., 2010; Vares et al., 2013; Pal et al., 2017) .
Microscopy of Giemsa stained samples from lesions, including skin scrapings, fine needle aspirates, or slit-skin smears, remains the reference test for diagnosis of the different forms of dermal leishmaniasis. However, microscopy has a low and variable sensitivity and requires trained and experienced personnel (de Vries et al., 2015; Adams et al., 2013) . As a result a high number of patients are put on treatment without laboratory confirmation, exposing a variable number of them to unnecessary toxic treatment (Zijlstra et al., 2017; World Health Organization, 2016) . The technical complexity and cost of the more sensitive molecular techniques (e.g. PCR) limits their application as routine diagnostic tools in endemic areas. Other simpler tests for detection of leishmanial DNA, such as loop-mediated isothermal amplification (LAMP) , are yet to be implemented (de Vries et al., 2015; Adams et al., 2018; Verma et al., 2017) . Other approaches include serology, which may be useful for screening of PKDL and mucosal leishmaniasis, but cannot be used for confirmation as presence of antibodies may be due to previous episodes or exposure to the parasite by living in endemic areas. The leishmanin skin test (LST) can also aid in the diagnosis of CL, but again the tests is not a marker of active infection, and therefore has limited value (WHO Expert Committee on the Control of the Leishmaniases and World Health Organization, 2010; Zijlstra et al., 2017; de Vries et al., 2015) .
Thus there is a great need for point-of-care (POC) tests for early diagnosis of dermal leishmaniases, in order to benefit both patients and communities by early identification of those that need treatment, reducing the risk of both sequelae and ongoing Leishmania transmission. It is then important that new POC tests to be developed meet the needs of the target population and the requirements for implementation in resource-limited settings, where most cases of dermal leishmaniasis occur. To this end we present here a Target Product Profile (TPP) for a POC test for dermal leishmaniases that was defined through consensus with stakeholders and experts in these forms of leishmaniases.
Methods
Target Product Profiles (TPPs) for diagnostics provide details on the desired minimal and optimal features of priority diagnostic tests, including performance and operational characteristics. Adherence to TPPs ensures that research and development activities are focused on products designed for the contexts and needs of end users. To develop a TPP for a POC for dermal leishmaniases we followed a three steps process: i) a draft TPP was developed by the leishmaniasis groups at the Foundation for Innovative New Diagnostics (FIND) and Drug for Neglected Diseases initiative (DNDi), ii) the draft TPP was discussed at a meeting of experts in leishmaniasis, and a revised version was prepared, then iii) the revised version was reviewed through an online survey with a larger audience of stakeholders and experts, and a consensus TPP developed.
The draft TPP had 29 test features for which optimal (desired) and minimally accepted targets were defined. This first draft was presented at the 2nd redeLEISH Meeting (Medellín, Colombia, July 2015) for discussion with a panel of 70 experts on leishmaniasis (DNDi.www.dndi.org, 2015) . The draft was refined based on the inputs received from experts in that meeting, and a new document prepared to be shared with a second panel of experts. Eighty-two experts in leishmaniasis and stakeholders were invited to participate in an online review of the TPP. Participants were requested to indicate their level of agreement with the optimal and minimal targets proposed for each feature, using a scale from 1 to 5, where 1 = Disagree, 2 = Somewhat disagree, 3 = Neither agree or disagree, 4 = Mostly agree and 5 = Fully agree. Where the level of agreement was 3 or less, the experts were requested to provide an explanation. The consensus among experts was scored as the percentage that indicated a level of agreement of N4 (mostly agree or 5, fully agree).
Results
Out of 82 experts invited to participate in the online review, 31 completed the full questionnaire indicating their level of agreement with each of the features in the TPP. The experts were drawn from different endemic regions and types of organizations (Fig. 1) .
There was consensus on all features (i.e. N50% of replies were either "mostly agree" or "fully agree"). The consensus scores were high for both the optimal (mean % of replies scoring 4 or 5 = 92.5 ± 9.3) and minimal targets (88.5 ± 11.1). Details on the features of TPP defined and the consensus scores for each of them is given in Table 1 .
Discussion
Due to the low sensitivity and/or specificity, as well as the complexity of some of the techniques currently available for CL diagnosis, most patients do not have access to early and reliable diagnosis, which increases morbidity and decreases the possibility of control. To advance CL control, new diagnostic options that are affordable, simple, specific, sensitive, and robust are still needed, preferably in the format of a rapid diagnostic test.
Stakeholders and experts in leishmaniasis participated in the development of the TPP described here, which can be used to guide product development. The aim should be for a rapid (b1 h), simple (b10 steps) and robust (stable at defined temperature and humidity) test that can be implemented in resource-limited settings enabling decentralized management of dermal leishmaniases. Ideally the test can be used to diagnose all forms of dermal leishmaniases, including CL and its complicated forms as well as PKDL. The minimally accepted target would be localized CL, the most prevalent, and the one that if diagnosed early, would reduce the risk of developing other forms such as mucosal leishmaniasis and cutaneous leishmaniasis recidivans. The targeted sensitivity should be at least 95% in parasitologically confirmed patients. Specificity should reach a minimum of 90%, to avoid treating nonleishmaniasis patients with other dermal conditions. The experts who participated in the process of developing the TPP described here agreed that the POC test should target Leishmania antigens. Optimally, the test should be able to identify Leishmania species, as this enable the adaptation of treatment according to the infecting species. However, a test with broad specificity for the whole Leishmania genus would be a minimally accepted target, a test able to detect an antigen that is common across species and that can be used with different sample types may present additional advantages: (i) it can be used to diagnose CL caused by species of both the Leishmania and Viannia subgenera, (ii) it can be used as well to diagnose other clinical forms evolving from CL such as ML, CLR and DCL; and (iii) by detecting species of the L. donovani complex, the diagnosis of PKDL and VL (if the test can also be used in urine or blood) would be possible.
An important aspect to take into consideration during test development would be its affordability. Features related to the test price were the most discussed by experts, and for these lower consensus scores were obtained (see Table 1 , features 27-29). Dermal leishmaniases mainly affect poor populations in low and middle income countries that have limited resources to address public health issues. As a consequence, the resources devoted to improving their management and control are scarce. However interventions that allow early detection and treatment would contribute to reducing a huge burden of disease, which is often overlooked, and indirectly, poverty (Bailey et al., 2017) . The TPP of a POC diagnostic test for dermal leishmaniases described here could be an important guide in the development of such a test.
